

Center for Drug Evaluation and Research

List of Licensed Biological Products with (1) Reference Product Exclusivity and (2) Biosimilarity or Interchangeability Evaluations to Date

BLA STN	PRODUCT (PROPER) NAME	PROPRIETARY NAME	DATE OF LICENSURE (mo/day/yr)	DATE OF FIRST LICENSURE (mo/day/yr)	REFERENCE PRODUCT EXCLUSIVITY EXPIRY DATE (mo/day/yr)	INTERCHANGEABLE (I)/ BIOSIMILAR (B)	WITHDRAWN
125118	abatacept	Orencia	12/23/05	NA	NA		
103575	abciximab	ReoPro	12/22/94	NA	NA		
125274	abobotulinumtoxinA	Dysport	04/29/09				
125057	adalimumab	Humira	12/31/02	NA	NA		
761071	adalimumab-adaz	Hyrimoz	10/30/18			B	
761058	adalimumab-adbm	Cyltezo	08/25/17			B	
761024	adalimumab-atto	Amjevita	09/23/16			B	
125427	ado-trastuzumab emtansine	Kadcyla	02/22/13				
125387	aflibercept	Eylea	11/18/11				
103979	agalsidase beta	Fabrazyme	04/24/03	NA	NA		
125431	albiglutide	Tanzeum	04/15/14				
103293	aldesleukin	Proleukin	05/05/92	NA	NA		
103948	alemtuzumab	Campath, Lemtrada	05/07/01	NA	NA		
125141	alglucosidase alfa	Myozyme	04/28/06	NA	NA		
125291	alglucosidase alfa	Lumizyme	05/24/10				
125559	alirocumab	Praluent	07/24/15				
103172	alteplase, cathflo activase	Activase	11/13/87	NA	NA		
103950	anakinra	Kineret	11/14/01	NA	NA		
125513	asfotase alfa	Strensiq	10/23/15				
101063	asparaginase	Elspar	01/10/78	NA	NA		
125359	asparaginase erwinia chrysanthemi	Erwinaze	11/18/11				
761034	atezolizumab	Tecentriq	05/18/16				
761049	avelumab	Bavencio	03/23/17				
103764	basiliximab	Simulect	05/12/98	NA	NA		
103691	becaplermin	Regranex	12/16/97	NA	NA		
125288	belatacept	Nulojx	06/15/11				
125370	belimumab	Benlysta	03/09/11				
761043	belimumab	Benlysta	07/20/17				
761070	benralizumab	Fasenra	11/14/17				
125085	bevacizumab	Avastin	02/26/04	NA	NA		
761028	bevacizumab-awwb	Mvasi	09/14/17			B	
761046	bezlotoxumab	Zinplava	10/21/16				
125557	blinatumomab	Blinicyto	12/03/14				
125388	brentuximab vedotin	Adcetris	08/19/11				
761032	brodalumab	Siliq	02/15/17				
761068	burosumab-twza	Crysvita	04/17/18				
761102	calaspargase pegol-mknl	Asparlas	12/20/18				
125319	canakinumab	Ilaris	06/17/09				
761112	caplacizumab-yhdp	Cablivi	02/06/19				
103608	capromab pendetide	ProstaScint	10/28/96	NA	NA		
761097	cemiplimab-rwlc	Libtayo	09/28/18				
761094	cenegermin-bkbj	Oxervate	08/22/18				
761052	cerliponase alfa	Brineura	04/27/17				
125160	certolizumab pegol	Cimzia	04/22/08				
125084	cetuximab	Erbix	02/12/04	NA	NA		
101995	collagenase	Santyl	06/04/65	NA	NA		
125338	collagenase clostridium histolyticum	Xiaflex	02/02/10				
103749	daclizumab	Zenapax	12/10/97	NA	NA		Yes
761029	daclizumab	Zinbryta	05/27/16				Yes
761036	daratumumab	Darzalex	11/16/15				
103951	darbepoetin alfa	Aranesp	09/17/01	NA	NA		

Center for Drug Evaluation and Research

List of Licensed Biological Products with (1) Reference Product Exclusivity and (2) Biosimilarity or Interchangeability Evaluations to Date

BLA STN	PRODUCT (PROPER) NAME	PROPRIETARY NAME	DATE OF LICENSURE (mo/day/yr)	DATE OF FIRST LICENSURE (mo/day/yr)	REFERENCE PRODUCT EXCLUSIVITY EXPIRY DATE (mo/day/yr)	INTERCHANGEABLE (I)/ BIOSIMILAR (B)	WITHDRAWN
103767	denileukin diftitox	Ontak	02/05/99	NA	NA		
125320	denosumab	Prolia, Xgeva	06/01/10				
125516	dinutuximab	Unituxin	03/10/15				
103532	dornase alfa	Pulmozyme	12/30/93	NA	NA		
125469	dulaglutide	Trulicity	09/18/14				
761055	dupilumab	Dupixent	03/28/17				
761069	durvalumab	Imfinzi	05/01/17				
125277	ecallantide	Kalbitor	12/01/09				
125166	eculizumab	Soliris	03/16/07	NA	NA		
761092	elapegedemase-lvlr	Revcovi	10/05/18				
125460	elosulfase alfa	Vimizim	02/14/14				
761035	elotuzumab	Empliciti	11/30/15				
761107	emapalumab-lzsg	Gamifant	11/20/18				
761083	emicizumab-kxwh	Hemlibra	11/16/17				
103234	epoetin alfa	Epogen/Procrit	06/01/89	NA	NA		
125545	epoetin alfa-epbx	Retacrit	05/15/18			B	
761077	erenumab-aooe	Aimovig	05/17/18				
103795	etanercept	Enbrel	11/02/98	NA	NA		
761042	etanercept-szsz	Erelzi	08/30/16			B	
125522	evolocumab	Repatha	08/27/15				
103353	filgrastim	Neupogen	02/20/91	NA	NA		
761080	filgrastim-aafi	Nivestym	07/20/18			B	
125553	filgrastim-sndz	Zarxio	03/06/15			B	
761089	fremanezumab-vfrm	Ajovy	09/14/18				
761063	galcanezumab-gnlm	Emgality	09/27/18				
125117	galsulfase	Naglazyme	05/31/05	NA	NA		
761060	gemtuzumab ozogamicin	Mylotarg	09/01/17				
125327	glucarpidase	Voraxaze	01/17/12				
125289	golimumab	Simponi	04/24/09				
125433	golimumab	Simponi Aria	07/18/13				
761061	guselkumab	Tremfya	07/13/17				
761065	ibalizumab-uiyk	Trogarzo	03/06/18				
125019	ibritumomab tiuxetan	Zevalin	02/19/02	NA	NA		
761025	idarucizumab	Praxbind	10/16/15				
125151	idursulfase	Elaprase	07/24/06	NA	NA		
125360	incobotulinumtoxinA	Xeomin	07/30/10				
103772	infliximab	Remicade	08/24/98	NA	NA		
761054	infliximab-abda	Renflexis	04/21/17			B	
125544	infliximab-dyyb	Inflectra	04/05/16			B	
761072	infliximab-qbtx	Ixifi	12/13/17			B	
761040	inotuzumab ozogamicin	Besponsa	08/17/17				
103132	interferon alfa-2b	Intron A	06/04/86	NA	NA		
103158	interferon alfa-n3	Alferon N Injection	10/10/89	NA	NA		
103628	interferon beta-1a	Avonex	05/17/96	NA	NA		
103780	interferon beta-1a	Rebif	03/07/02	NA	NA		
103471	interferon beta-1b	Betaseron	07/23/93	NA	NA		
125290	interferon beta-1b	Extavia	08/14/09				
103836	interferon gamma-1b	Actimmune	02/25/99	NA	NA		
125377	ipilimumab	Yervoy	03/25/11				
125521	ixekizumab	Taltz	03/22/16				
761090	lanadelumab-flyo	Takhzyro	08/23/18				

Center for Drug Evaluation and Research

List of Licensed Biological Products with (1) Reference Product Exclusivity and (2) Biosimilarity or Interchangeability Evaluations to Date

BLA STN	PRODUCT (PROPER) NAME	PROPRIETARY NAME	DATE OF LICENSURE (mo/day/yr)	DATE OF FIRST LICENSURE (mo/day/yr)	REFERENCE PRODUCT EXCLUSIVITY EXPIRY DATE (mo/day/yr)	INTERCHANGEABLE (I)/ BIOSIMILAR (B)	WITHDRAWN
125058	laronidase	Aldurazyme	04/30/03	NA	NA		
125526	mepolizumab	Nucala	11/04/15				
125164	methoxy polyethylene glycol-epoetin beta	Mircera	11/14/07				
125390	metreleptin	Myalept	02/24/14				
761051	mogamulizumab-kpkc	Poteligeo	08/08/18				
761104	moxetumomab pasudotox-tdfk	Lumoxiti	09/13/18				
125104	natalizumab	Tysabri	11/23/04	NA	NA		
125547	necitumumab	Portrazza	11/24/15				
125554	nivolumab	Opdivo	12/22/14				
125509	obiltoximab	Anthim	03/18/16				
125486	obinutuzumab	Gazyva	11/01/13				
761053	ocrelizumab	Ocrevus	03/28/17				
125422	ocriplasmin	Jetrea	10/17/12				
125326	ofatumumab	Arzerra	10/26/09				
761038	olaratumab	Lartruvo	10/19/16				
103976	omalizumab	Xolair	06/20/03	NA	NA		
103000	onabotulinumtoxinA	Botox	12/29/89	NA	NA		
103694	oprelvekin	Neumega	11/25/97	NA	NA		Yes
125103	palifermin	Kepivance	12/15/04	NA	NA		
103770	palivizumab	Synagis	06/19/98	NA	NA		
125147	panitumumab	Vectibix	09/27/06	NA	NA		
125511	parathyroid hormone	Natpara	01/23/15				
103411	pegaspargase	Oncaspar	02/01/94	NA	NA		
125031	pegfilgrastim	Neulasta	01/31/02	NA	NA		
761039	pegfilgrastim-cbqv	Udenyca	11/02/18			B	
761075	pegfilgrastim-jmdb	Fulphila	06/04/18			B	
103964	peginterferon alfa-2a	Pegasys	10/16/02	NA	NA		
125083	peginterferon alfa-2a co-packaged with ribavirin	Pegasys Copegus Combination Pack	06/04/04	NA	NA		Yes
103949	peginterferon alfa-2b	PegIntron, Sylatron	01/19/01	NA	NA		
125499	peginterferon beta-1a	Plegridy	08/15/14				
125293	pegloticase	Krystexxa	09/14/10				
761079	pegvaliase-pqpz	Palynziq	05/24/18				
125514	pembrolizumab	Keytruda	09/04/14				
125409	pertuzumab	Perjeta	06/08/12	06/08/12	06/08/24		
761085	prabotulinumtoxinA-xvfs	Jeuveau	02/01/19				
125477	ramucirumab	Cyramza	04/21/14				
125156	ranibizumab	Lucentis	06/30/06	NA	NA		
103946	rasburicase	Elitek	07/12/02	NA	NA		
761108	ravulizumab-cwvz	Ultomiris	12/21/18				
125349	raxibacumab	raxibacumab	12/14/12				
761033	reslizumab	Cinqair	03/23/16				
103786	reteplase	Retavase	10/30/96	NA	NA		
125249	rilonacept	Arcalyst	02/27/08				
103846	rimabotulinumtoxinB	Myobloc	12/08/00	NA	NA		
761105	risankizumab-rzaa	Skyrizi	04/23/19				
103705	rituximab	Rituxan	11/26/97	NA	NA		
761088	rituximab-abbs	Truxima	11/28/18			B	
761064	rituximab and hyaluronidase human	Rituxan Hycela	06/22/17				
125268	romiplostim	Nplate	08/22/08				
761062	romosozumab-aqqg	Evenity	04/09/19				
103362	sargramostim	Leukine	03/05/91	NA	NA		

Center for Drug Evaluation and Research

List of Licensed Biological Products with (1) Reference Product Exclusivity and (2) Biosimilarity or Interchangeability Evaluations to Date

BLA STN	PRODUCT (PROPER) NAME	PROPRIETARY NAME	DATE OF LICENSURE (mo/day/yr)	DATE OF FIRST LICENSURE (mo/day/yr)	REFERENCE PRODUCT EXCLUSIVITY EXPIRY DATE (mo/day/yr)	INTERCHANGEABLE (I)/ BIOSIMILAR (B)	WITHDRAWN
761037	sarilumab	Kevzara	05/22/17				
125561	sebelipase alfa	Kanuma	12/08/15				
125504	secukinumab	Cosentyx	01/21/15				
125496	siltuximab	Sylvant	04/23/14				
761116	tagraxofusp-erzs	Elzonris	12/21/18				
125294	tbo-filgrastim	Granix	08/29/12	08/29/12	08/29/24		
103909	tenecteplase	TNKase	06/02/00	NA	NA		
761067	tildrakizumab-asmn	Ilumya	03/20/18				
125276	tocilizumab	Actemra	01/08/10				
125472	tocilizumab	Actemra	10/21/13				
103792	trastuzumab	Herceptin	09/25/98	NA	NA		
761074	trastuzumab-dkst	Ogivri	12/01/17			B	
761100	trastuzumab-dttb	Ontruzant	01/18/19			B	
761091	trastuzumab-pkrb	Herzuma	12/14/18			B	
761081	trastuzumab-qyyp	Trazimera	03/11/19			B	
761106	trastuzumab and hyaluronidase-oysk	Herceptin Hylecta	02/28/19				
125261	ustekinumab	Stelara	09/25/09				
761044	ustekinumab	Stelara	09/23/16				
125476	vedolizumab	Entyvio	05/20/14				
761047	vestronidase alfa-vjbc	Mepsevii	11/15/17				
125418	ziv-aflibercept	Zaltrap	08/03/12				

Center for Drug Evaluation and Research
List of Licensed Biological Products with (1) Reference Product Exclusivity and (2) Biosimilarity or Interchangeability Evaluations to Date

BLA STN	PRODUCT (PROPER) NAME	PROPRIETARY NAME	DATE OF LICENSURE (mo/day/yr)	DATE OF FIRST LICENSURE (mo/day/yr)	REFERENCE PRODUCT EXCLUSIVITY EXPIRY DATE (mo/day/yr)	INTERCHANGEABLE (I)/ BIOSIMILAR (B)	WITHDRAWN
---------	-----------------------	------------------	----------------------------------	---	---	--	-----------

Key -

BLA STN: Biologic License Application Submission Tracking Number

Product (Proper) Name: The nonproprietary name designated by FDA for a biological product at the time of licensure under the PHS Act (section 351(a)(1)(B)(i) of the PHS Act and 21 CFR 600.3(k) of the FD&C Act).

Proprietary Name: Brand/Trade Name

Date of Licensure: The date the application was approved/licensed for marketing. Date of licensure for each application was identified through FDA records.

Date of First Licensure: The date from which reference product exclusivity began to run. Under 351(k)(7)(C), the date of first licensure will not be the date a particular application was licensed if that application is a subsequent application filed by the same or related sponsor of the biological product for a change (not including a modification to the structure of its previously approved biological product) that results in a new indication, route of administration, dosing schedule, dosage form, delivery system, delivery device, or strength, or if the change is a modification to the structure of the previously approved biological product that does not result in a change in safety, purity, or potency.

FDA will generally make a determination of date of first licensure for reasons of regulatory necessity and/or at the request of the 351(a) application license holder.

The Agency will denote the date of first licensure as “not applicable” (NA) if:

- The product was licensed under 351(a) and the date it was licensed falls under any exclusion identified in 351(k)(7)(C) or
- More than 12 years (or 12 years and 6 months in the case of a product that has earned pediatric exclusivity) have passed since the date of licensure of the product, and thus any reference product exclusivity that the product may have had would have expired, thus obviating the need for a determination of whether any exclusion under 351(k)(7)(C) applies.

In such cases, a corresponding NA notation will also be placed in the next column, “Reference Product Exclusivity Expiry Date”.

Reference Product Exclusivity Expiry Date: The reference product exclusivity expiry date indicates (1) the date that is 12 years from the date of first licensure as described in 351(k)(7); plus (2) any pediatric exclusivity granted pursuant to section 505(A) of the FD&C Act, if applicable. The reference product exclusivity expiry date is the date on which a 351(k) application referencing the reference product may be licensed assuming it is not blocked by orphan exclusivity and otherwise meets the requirements for licensure under 351(k). To determine whether there is unexpired orphan exclusivity for an indication for which the reference product is licensed, please refer to the searchable database for Orphan Designated and/or Approved Products (<http://www.fda.gov/ForIndustry/DevelopingProductsforRareDiseasesConditions/HowtoapplyforOrphanProductDesignation/default.htm>).

For the explanation of the notation “NA,” please see the definition of “Date of First Licensure” above.

Interchangeable (I)/Biosimilar (B): Identification of those biological products approved/licensed under 351(k) that were licensed as either interchangeable with or biosimilar to the reference product. Such products will be listed under the 351(a) BLA referenced in the 351(k) application. Biosimilarity has been demonstrated for the condition(s) of use (e.g., indication(s), dosing regimen(s)), strength(s), dosage form(s), and route(s) of administration described in the biosimilar product’s Full Prescribing Information.

Withdrawn: The BLA has been withdrawn or is no longer being marketed. This does not specify whether withdrawn for reasons of safety and/or effectiveness.

Note: The List of Licensed Biological Products with (1) Reference Product Exclusivity and (2) Biosimilarity or Interchangeability Evaluations reflects all BLAs that were active at the time the “Purple Book” was originally published on September 9, 2014. FDA will continue to update the list when FDA licenses a biological product under section 351(a) or section 351(k) of the PHS Act and/or makes a determination regarding date of first licensure for a biological product licensed under section 351(a) of the PHS Act, and to reflect other changes in the status of these biological products, as appropriate.